Cargando…
PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases
Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases. However, due to the exponential growth in drug development, it would be impractica...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623281/ https://www.ncbi.nlm.nih.gov/pubmed/36330216 http://dx.doi.org/10.3389/fmolb.2022.971768 |
_version_ | 1784821962665623552 |
---|---|
author | Hong, Yongkai Chen, Dantian Jin, Yaqing Zu, Mian Zhang, Yin |
author_facet | Hong, Yongkai Chen, Dantian Jin, Yaqing Zu, Mian Zhang, Yin |
author_sort | Hong, Yongkai |
collection | PubMed |
description | Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases. However, due to the exponential growth in drug development, it would be impractical to evaluate all combinations through experiments. In view of this, we developed Pathway Interaction Network (PINet) biological model to estimate the optimal drug combinations for various diseases. The random walk with restart (RWR) algorithm was used to capture the “disease state” and “drug state,” while PINet was used to evaluate the optimal drug combinations and the high-order drug combination. The model achieved a mean area under the curve of a receiver operating characteristic curve of 0.885. In addition, for some diseases, PINet predicted the optimal drug combination. For example, in the case of acute myeloid leukemia, PINet correctly predicted midostaurin and gemtuzumab as effective drug combinations, as demonstrated by the results of a Phase-I clinical trial. Moreover, PINet also correctly predicted the potential drug combinations for diseases that lacked a training dataset that could not be predicted using standard machine learning models. |
format | Online Article Text |
id | pubmed-9623281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96232812022-11-02 PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases Hong, Yongkai Chen, Dantian Jin, Yaqing Zu, Mian Zhang, Yin Front Mol Biosci Molecular Biosciences Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases. However, due to the exponential growth in drug development, it would be impractical to evaluate all combinations through experiments. In view of this, we developed Pathway Interaction Network (PINet) biological model to estimate the optimal drug combinations for various diseases. The random walk with restart (RWR) algorithm was used to capture the “disease state” and “drug state,” while PINet was used to evaluate the optimal drug combinations and the high-order drug combination. The model achieved a mean area under the curve of a receiver operating characteristic curve of 0.885. In addition, for some diseases, PINet predicted the optimal drug combination. For example, in the case of acute myeloid leukemia, PINet correctly predicted midostaurin and gemtuzumab as effective drug combinations, as demonstrated by the results of a Phase-I clinical trial. Moreover, PINet also correctly predicted the potential drug combinations for diseases that lacked a training dataset that could not be predicted using standard machine learning models. Frontiers Media S.A. 2022-10-18 /pmc/articles/PMC9623281/ /pubmed/36330216 http://dx.doi.org/10.3389/fmolb.2022.971768 Text en Copyright © 2022 Hong, Chen, Jin, Zu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Hong, Yongkai Chen, Dantian Jin, Yaqing Zu, Mian Zhang, Yin PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases |
title | PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases |
title_full | PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases |
title_fullStr | PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases |
title_full_unstemmed | PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases |
title_short | PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases |
title_sort | pinet 1.0: a pathway network-based evaluation of drug combinations for the management of specific diseases |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623281/ https://www.ncbi.nlm.nih.gov/pubmed/36330216 http://dx.doi.org/10.3389/fmolb.2022.971768 |
work_keys_str_mv | AT hongyongkai pinet10apathwaynetworkbasedevaluationofdrugcombinationsforthemanagementofspecificdiseases AT chendantian pinet10apathwaynetworkbasedevaluationofdrugcombinationsforthemanagementofspecificdiseases AT jinyaqing pinet10apathwaynetworkbasedevaluationofdrugcombinationsforthemanagementofspecificdiseases AT zumian pinet10apathwaynetworkbasedevaluationofdrugcombinationsforthemanagementofspecificdiseases AT zhangyin pinet10apathwaynetworkbasedevaluationofdrugcombinationsforthemanagementofspecificdiseases |